Enanta Pharmaceuticals Company Profile (NASDAQ:ENTA)

About Enanta Pharmaceuticals

Enanta Pharmaceuticals logoEnanta Pharmaceuticals Inc. is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create molecule drugs primarily for the treatment of viral infections and liver diseases. The Company is engaged in discovering and developing inhibitors designed for use against the hepatitis C virus (HCV), as well as compounds for non-alcoholic steatohepatitis (NASH) and primary biliary cirrhosis (PBC). The Company is involved in a program to develop nucleotide inhibitors to HCV NS5B polymerase. In its NASH program, the Company is developing agonists of the farnesoid X receptor, or FXR, that are designed to bind to that receptor and then trigger a response from it. The Company is also engaged in a program in PBC, another disease of the liver that can result in liver damage, liver failure, or hepatocellular carcinoma. Its pipeline of products includes Paritaprevir, ABT-493, EDP-239, ABT-494 and EDP-494.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ENTA
  • CUSIP:
Key Metrics:
  • Previous Close: $26.15
  • 50 Day Moving Average: $23.46
  • 200 Day Moving Average: $25.04
  • 52-Week Range: $16.75 - $41.77
  • Trailing P/E Ratio: 17.29
  • Foreward P/E Ratio: -174.33
  • P/E Growth: 0.00
  • Market Cap: $497.77M
  • Outstanding Shares: 19,035,000
  • Beta: 0.58
Profitability:
  • Net Margins: 32.59%
  • Return on Equity: 11.31%
  • Return on Assets: 10.77%
Debt:
  • Current Ratio: 25.29%
  • Quick Ratio: 25.29%
Additional Links:
Companies Related to Enanta Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Enanta Pharmaceuticals (NASDAQ:ENTA) (?)
Ratings Breakdown: 1 Sell Rating, 2 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $24.50 (6.31% downside)

Analysts' Ratings History for Enanta Pharmaceuticals (NASDAQ:ENTA)
Show:
DateFirmActionRatingPrice TargetDetails
8/9/2016JPMorgan Chase & Co.Set Price TargetBuy$31.00 -> $26.00View Rating Details
4/28/2016JMP SecuritiesDowngradeOutperform -> Market PerformView Rating Details
2/9/2016Barclays PLCBoost Price TargetUnderweight$16.00 -> $18.00View Rating Details
2/9/2016Robert W. BairdReiterated RatingNeutral$36.00 -> $22.00View Rating Details
5/8/2015Leerink SwannLower Price TargetOutperform$42.00 -> $41.00View Rating Details
4/6/2015Deutsche Bank AGInitiated CoverageBuy$42.00 -> $42.00View Rating Details
11/24/2014FBR & CoReiterated RatingOutperform$50.00View Rating Details
(Data available from 9/26/2014 forward)

Earnings

Earnings History for Enanta Pharmaceuticals (NASDAQ:ENTA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/21/2016        
8/8/2016Q216($0.09)($0.06)$13.07 million$14.00 millionViewListenView Earnings Details
5/9/2016Q2$0.10($0.09)$16.80 million$13.00 millionViewListenView Earnings Details
2/8/2016Q116$1.13$1.36$47.32 million$48.40 millionViewListenView Earnings Details
11/23/2015Q415$0.15$0.29$16.44 million$14.40 millionViewListenView Earnings Details
8/6/2015Q315$0.19$0.13$16.18 million$11.60 millionViewListenView Earnings Details
5/7/2015Q215$1.80$1.49$63.40 million$57.40 millionViewListenView Earnings Details
2/5/2015Q115$3.82$2.18$86.62 million$77.50 millionViewN/AView Earnings Details
11/24/2014Q414($0.33)($0.27)$3.81 million$2.60 millionViewListenView Earnings Details
8/11/2014Q314$1.67$2.61$40.83 million$42.10 millionViewN/AView Earnings Details
5/12/2014Q2$0.69($0.28)$1.20 million$2.20 millionViewListenView Earnings Details
2/13/2014Q114($0.15)($0.30)$1.41 million$0.89 millionViewN/AView Earnings Details
11/25/2013Q4($0.29)($0.25)$1.00 million$1.30 millionViewListenView Earnings Details
8/12/2013Q213($0.34)($0.23)$0.73 million$1.60 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Enanta Pharmaceuticals (NASDAQ:ENTA)
Current Year EPS Consensus Estimate: $1.02 EPS
Next Year EPS Consensus Estimate: $-0.15 EPS

Dividends

Dividend History for Enanta Pharmaceuticals (NASDAQ:ENTA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Enanta Pharmaceuticals (NASDAQ:ENTA)
Insider Ownership Percentage: 7.90%
Institutional Ownership Percentage: 70.82%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/11/2016Nathaniel S GardinerVPBuy500$24.45$12,225.00View SEC Filing  
2/12/2016Terry VanceDirectorBuy2,000$27.04$54,080.00View SEC Filing  
11/24/2015Paul J. MellettCFOSell6,000$30.15$180,900.00View SEC Filing  
10/15/2015Paul J MellettCFOSell7,500$40.10$300,750.00View SEC Filing  
9/8/2015Paul J. MellettCFOSell7,500$39.55$296,625.00View SEC Filing  
7/13/2015Paul J MellettCFOSell7,500$46.29$347,175.00View SEC Filing  
7/13/2015Yat Sun OrInsiderSell3,750$46.29$173,587.50View SEC Filing  
6/11/2015Paul J MellettCFOSell7,500$42.51$318,825.00View SEC Filing  
6/11/2015Yat Sun OrInsiderSell3,750$42.47$159,262.50View SEC Filing  
6/5/2015Yat Sun OrInsiderSell10,750$42.02$451,715.00View SEC Filing  
5/19/2015Paul J MellettCFOSell24,000$40.13$963,120.00View SEC Filing  
5/11/2015Yat Sun OrInsiderSell8,000$36.13$289,040.00View SEC Filing  
3/9/2015Jay R LulyCEOSell15,000$33.37$500,550.00View SEC Filing  
2/20/2015Jay R LulyCEOSell15,000$35.35$530,250.00View SEC Filing  
2/19/2015Stephen Jr. BuckleyDirectorBuy1,000$34.00$34,000.00View SEC Filing  
2/17/2015Nathaniel S GardinerVPBuy1,400$33.23$46,522.00View SEC Filing  
1/16/2015Paul J MellettCFOSell4,500$49.45$222,525.00View SEC Filing  
1/5/2015Jay R LulyCEOSell15,000$50.43$756,450.00View SEC Filing  
12/1/2014Jay R LulyCEOSell15,000$45.39$680,850.00View SEC Filing  
11/3/2014Jay R LulyCEOSell15,000$42.52$637,800.00View SEC Filing  
9/15/2014Paul J MellettCFOSell10,000$39.83$398,300.00View SEC Filing  
8/14/2014Paul J MellettCFOSell10,000$39.13$391,300.00View SEC Filing  
8/14/2014Stephen Jr. BuckleyDirectorBuy1,000$38.95$38,950.00View SEC Filing  
7/14/2014Paul J MellettCFOSell20,000$39.88$797,600.00View SEC Filing  
5/1/2014Yat Sun OrInsiderSell5,000$36.98$184,900.00View SEC Filing  
4/1/2014Jay LulyCEOSell15,000$39.17$587,550.00View SEC Filing  
4/1/2014Yat Sun OrInsiderSell10,000$39.16$391,600.00View SEC Filing  
3/24/2014Yat Sun OrInsiderSell10,000$39.34$393,400.00View SEC Filing  
3/4/2014V Life Science Ventures Gm Tvmmajor shareholderSell439,334$38.82$17,054,945.88View SEC Filing  
2/26/2014V Life Science Ventures Gm Tvmmajor shareholderSell230,190$39.15$9,011,938.50View SEC Filing  
2/24/2014V Life Science Ventures Gm Tvmmajor shareholderSell60,477$39.57$2,393,074.89View SEC Filing  
2/14/2014Jay LulyCEOSell5,800$38.10$220,980.00View SEC Filing  
1/2/2014Jay R LulyCEOSell5,800$28.05$162,690.00View SEC Filing  
12/6/2013Marc E GoldbergDirectorSell6,861$27.93$191,627.73View SEC Filing  
10/14/2013Saints Capital Granite, L.P.Major ShareholderSell32,301$19.84$640,851.84View SEC Filing  
10/10/2013Saints Capital Granite, L.P.Major ShareholderSell36,207$21.71$786,053.97View SEC Filing  
10/3/2013Saints Capital Granite, L.P.Major ShareholderSell12,300$23.39$287,697.00View SEC Filing  
3/26/2013Helmut SchuhslerDirectorBuy132,949$14.00$1,861,286.00View SEC Filing  
3/26/2013Saints Capital Granite, L.P.Major ShareholderBuy66,474$14.00$930,636.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Enanta Pharmaceuticals (NASDAQ:ENTA)
DateHeadline
tmcnet.com logoEnanta Pharmaceuticals Announces Data on Eight-Week Treatment … (NASDAQ:ENTA)
www.tmcnet.com - September 24 at 4:37 PM
finance.yahoo.com logo6:08 am Enanta Pharmaceuticals announces new data showing high response rates with just eight weeks of VIEKIRAX (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA (dasabuvir tablets) treatment (NASDAQ:ENTA)
finance.yahoo.com - September 24 at 9:28 AM
streetinsider.com logoEnanta Pharma (ENTA) Announces New Data from VIEKIRAX + EXVIERA Phase 3 in Genotype 1b HCV - StreetInsider.com (NASDAQ:ENTA)
www.streetinsider.com - September 23 at 4:36 PM
streetinsider.com logoEnanta Pharma (ENTA) Announces New Data from VIEKIRAX + EXVIERA Phase 3 in Genotype 1b HCV (NASDAQ:ENTA)
www.streetinsider.com - September 23 at 9:50 AM
News IconAnalyst Consensus Estimates & Projections are in For Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Frisco Fastball (NASDAQ:ENTA)
friscofastball.com - September 22 at 10:26 AM
investornewswire.com logoShares Of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Expected To Hit $32 - Investor Newswire (NASDAQ:ENTA)
www.investornewswire.com - September 22 at 10:26 AM
investors.com logoLiver Disease Gets The Attention Of Several Major Biotech Companies (NASDAQ:ENTA)
www.investors.com - September 21 at 5:22 PM
rttnews.com logoEnanta Pharmaceuticals Inc. (ENTA) Has Re-crossed Its 200-Day Moving Average (NASDAQ:ENTA)
www.rttnews.com - September 21 at 8:47 AM
News IconStock Perspective: Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Earnings in View - Frisco Fastball (NASDAQ:ENTA)
friscofastball.com - September 7 at 4:59 PM
capitalcube.com logoEnanta Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ENTA-US : September 7, 2016 (NASDAQ:ENTA)
www.capitalcube.com - September 7 at 4:59 PM
News IconShares Holding Above Moving Averages: Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Post News (NASDAQ:ENTA)
www.kentuckypostnews.com - August 29 at 3:53 PM
capitalcube.com logoETF’s with exposure to Enanta Pharmaceuticals, Inc. : August 29, 2016 (NASDAQ:ENTA)
www.capitalcube.com - August 29 at 3:53 PM
businesswire.com logoEnanta Pharmaceuticals to Present at Two Upcoming Investor Conferences (NASDAQ:ENTA)
www.businesswire.com - August 29 at 9:29 AM
capitalcube.com logoEnanta Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ENTA-US : August 26, 2016 (NASDAQ:ENTA)
www.capitalcube.com - August 26 at 4:45 PM
investornewswire.com logoEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Gets 0 Recommendations To Sell - Investor Newswire (NASDAQ:ENTA)
www.investornewswire.com - August 25 at 4:52 PM
News IconCrowd Views on Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Post News (NASDAQ:ENTA)
www.kentuckypostnews.com - August 23 at 4:56 PM
finance.yahoo.com logoENANTA PHARMACEUTICALS INC Financials (NASDAQ:ENTA)
finance.yahoo.com - August 18 at 4:51 PM
investornewswire.com logoWill Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Hit $32 Price Target? - Investor Newswire (NASDAQ:ENTA)
www.investornewswire.com - August 17 at 5:02 PM
capitalcube.com logoETF’s with exposure to Enanta Pharmaceuticals, Inc. : August 12, 2016 (NASDAQ:ENTA)
www.capitalcube.com - August 12 at 4:53 PM
capitalcube.com logoEnanta Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ENTA-US : August 11, 2016 (NASDAQ:ENTA)
www.capitalcube.com - August 11 at 4:59 PM
capitalcube.com logoEnanta Pharmaceuticals, Inc. :ENTA-US: Earnings Analysis: Q3, 2016 By the Numbers : August 10, 2016 (NASDAQ:ENTA)
www.capitalcube.com - August 10 at 5:00 PM
biz.yahoo.com logoENANTA PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report (NASDAQ:ENTA)
biz.yahoo.com - August 9 at 9:05 PM
finance.yahoo.com logoEdited Transcript of ENTA earnings conference call or presentation 8-Aug-16 8:30pm GMT (NASDAQ:ENTA)
finance.yahoo.com - August 9 at 6:49 AM
4-traders.com logoEnanta Pharmaceuticals : reports 3Q loss (NASDAQ:ENTA)
www.4-traders.com - August 8 at 10:12 PM
News IconEnanta Pharmaceuticals Reports Financial ... (NASDAQ:ENTA)
ih.advfn.com - August 8 at 4:58 PM
sg.finance.yahoo.com logoEnanta Pharmaceuticals reports 3Q loss (NASDAQ:ENTA)
sg.finance.yahoo.com - August 8 at 4:58 PM
biz.yahoo.com logoQ3 2016 Enanta Pharmaceuticals Inc Earnings Release - After Market Close (NASDAQ:ENTA)
biz.yahoo.com - August 8 at 9:38 AM
ftsenews.co.uk logoNew Broker Ratings For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - FTSE News (NASDAQ:ENTA)
www.ftsenews.co.uk - August 5 at 7:29 AM
publicnow.com logoEnanta Announces the U.S. Food and Drug Administration has approved AbbVie’s New, Once-Daily VIEKIRA XR™ (dasabuvir, ombitasvir, paritaprevir and ritonavir) for the Treatment of Genotype 1 Chronic Hepatitis C Virus (NASDAQ:ENTA)
www.publicnow.com - August 2 at 9:38 AM
equities.com logoEnanta Pharmaceuticals Inc. (ENTA) Jumps 7.1% on July 29 - Equities.com (NASDAQ:ENTA)
www.equities.com - July 30 at 7:26 AM
investornewswire.com logoCan Shares Of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Hit $32? - Investor Newswire (NASDAQ:ENTA)
www.investornewswire.com - July 28 at 7:57 AM
nasdaq.com logoFDA Oks AbbVie' VIEKIRA XR To Treat Genotype 1 Chronic Hepatitis C Virus (NASDAQ:ENTA)
www.nasdaq.com - July 26 at 7:41 AM
tmcnet.com logoEnanta Announces the U.S. Food and Drug … (NASDAQ:ENTA)
www.tmcnet.com - July 25 at 10:20 PM
finance.yahoo.com logoCHMP Grants Positive Opinion for Shorter Treatment Duration with AbbVie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) for Patients with Genotype 4 Chronic Hepatitis C with Compensated Cirrhosis (Child-Pugh A) (NASDAQ:ENTA)
finance.yahoo.com - July 25 at 4:00 AM
news.cmlviz.com logoEnanta Pharmaceuticals Inc (NASDAQ:ENTA) Realized Volatility Hits An Elevated Level - CML News (NASDAQ:ENTA)
news.cmlviz.com - July 23 at 8:55 AM
News IconHays Advisory Lowers stake in Enanta Pharmaceuticals Inc (ENTA) - TheFounders Daily (NASDAQ:ENTA)
www.thefoundersdaily.com - July 23 at 8:55 AM
News IconEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily (NASDAQ:ENTA)
www.engelwooddaily.com - July 22 at 7:31 AM
equities.com logoEnanta Pharmaceuticals Inc. (ENTA) Jumps 5.62% on July 21 - Equities.com (NASDAQ:ENTA)
www.equities.com - July 22 at 7:31 AM
News IconStock Soars, Rewards Investors Nicely Today: Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Engelwood Daily (NASDAQ:ENTA)
www.engelwooddaily.com - July 21 at 5:00 PM
capitalcube.com logoETF’s with exposure to Enanta Pharmaceuticals, Inc. : July 21, 2016 (NASDAQ:ENTA)
www.capitalcube.com - July 21 at 1:59 PM
equities.com logoEnanta Pharmaceuticals Inc. (ENTA) is Trading Lower on Unusual Volume for July 19 - Equities.com (NASDAQ:ENTA)
www.equities.com - July 21 at 8:20 AM
investornewswire.com logoIs $32 Price Target Attainable For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)? - Investor Newswire (NASDAQ:ENTA)
www.investornewswire.com - July 20 at 6:03 PM
News IconEquity Roundup: Stock Performance Focus on Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Press Telegraph (NASDAQ:ENTA)
presstelegraph.com - July 20 at 7:28 AM
tmcnet.com logoEnanta Pharmaceuticals to Host Conference Call on August … (NASDAQ:ENTA)
www.tmcnet.com - July 19 at 10:05 PM
News IconShare Performance Summary for: Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Press Telegraph (NASDAQ:ENTA)
presstelegraph.com - July 18 at 9:57 AM
finance.yahoo.com logoEnanta Pharmaceuticals to Host Conference Call on August 8 at 4:30 P.M. ET to Discuss Financial Results for Its Fiscal Third Quarter Ended June 30, 2016 (NASDAQ:ENTA)
finance.yahoo.com - July 18 at 7:30 AM
News IconShares Experiencing a Downtrend: Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - TGP (NASDAQ:ENTA)
telanaganapress.com - July 16 at 8:14 AM
News IconEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Earnings Concentration and Analyst Target Watch - Engelwood Daily (NASDAQ:ENTA)
www.engelwooddaily.com - July 14 at 4:29 PM
News IconEnanta Pharmaceuticals Incorporated (NASDAQ:ENTA) Short Interest Decreased By 1.75% - Consumer Eagle (NASDAQ:ENTA)
www.consumereagle.com - July 14 at 4:29 PM
News IconShares Losing Ground for the Month; Investor Alert on Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Engelwood Daily (NASDAQ:ENTA)
www.engelwooddaily.com - July 14 at 8:03 AM

Social

Enanta Pharmaceuticals (NASDAQ:ENTA) Chart for Monday, September, 26, 2016


Last Updated on 9/26/2016 by MarketBeat.com Staff